Collaborative modeling of the benefits and harms associated with different U.S. Breast cancer screening strategies

Annals of Internal Medicine

Volumn 164, Issue 4, 2016, Pages 215-225

  Mandelblatt, Jeanne S ^a   Stout, Natasha K ^b   Schechter, Clyde B ^c   Van Den Broek, Jeroen J ^d   Miglioretti, Diana L ^e   Krapcho, Martin ^f   Trentham Dietz, Amy ^g   Munoz, Diego ^h   Lee, Sandra J ^a   Berry, Donald A ^j   Van Ravesteyn, Nicolien T ^d   Alagoz, Oguzhan ^k   Kerlikowske, Karla ^l   Tosteson, Anna N A ^m   Near, Aimee M ^a   Hoeffken, Amanda ^a   Chang, Yaojen ^a   Heijnsdijk, Eveline A ^d   Chisholm, Gary ^j   Huang, Xuelin ^a   Huang, Hui ^i,j   Ergun, Mehmet Ali ^k   Gangnon, Ronald ⁿ   Sprague, Brian L ^o   Plevritis, Sylvia ^p   Feuer, Eric ^q   De Koning, Harry J ^d   Cronin, Kathleen A ^i,q   more..

^a GEORGETOWN UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f INFORMATION MANAGEMENT SERVICES INC   (United States)

^g UNIVERSITY OF WISCONSIN   (United States)

^h STANFORD UNIVERSITY   (United States)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^k UNIVERSITY OF WISCONSIN MADISON   (United States)

^l SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^m DARTMOUTH MEDICAL SCHOOL   (United States)

ⁿ UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^o UNIVERSITY OF VERMONT   (United States)

^p STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^q NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; TAMOXIFEN; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; COMORBIDITY; DIAGNOSTIC ERROR; DIGITAL MAMMOGRAPHY; FALSE POSITIVE RESULT; FEMALE; HUMAN; HUMAN TISSUE; OUTCOME ASSESSMENT; OVERDIAGNOSIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SIMULATION; SYSTEMIC THERAPY; THERAPY; UNITED STATES; ADVERSE EFFECTS; AGE; ANATOMY AND HISTOLOGY; BREAST; BREAST NEOPLASMS; COMPUTER SIMULATION; EARLY CANCER DIAGNOSIS; INCIDENCE; LABORATORY DIAGNOSIS; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; MORTALITY; PROCEDURES; RADIOGRAPHY; RISK ASSESSMENT; TIME FACTOR;

ADULT; AGE FACTORS; AGED; BREAST; BREAST NEOPLASMS; COMORBIDITY; COMPUTER SIMULATION; EARLY DETECTION OF CANCER; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; INCIDENCE; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; RISK ASSESSMENT; TIME FACTORS; UNITED STATES;

EID: 84958818486     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M15-1536     Document Type: Article

References (75)

1. Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G, et al; Breast Cancer Working Group of the Cancer Intervention and Surveillance Modeling Network. Effects of mammogra-phy screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009;151:738-47. [PMID: 19920274] doi:10.7326/0003-4819-151-10-200911170-00010
2. Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013;6:CD001877. [PMID: 23737396] doi:10.1002/14651858.CD001877.pub5
3. Biller-Andorno N, Jüni P. Abolishing mammography screening programs? A view from the Swiss Medical Board. N Engl J Med. 2014;370:1965-7. [PMID: 24738641] doi:10.1056/NEJMp1401875
4. Nyströ m L, Andersson I, Bjurstam N, Frisell J, Nordenskjö ld B, Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet. 2002;359:909-19. [PMID: 11918907]
5. Tabá r L, Vitak B, Chen HH, Duffy SW, Yen MF, Chiang CF, et al. The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up. Radiol Clin North Am. 2000;38:625-51. [PMID: 10943268]
6. Moss SM, Cuckle H, Evans A, Johns L, Waller M, Bobrow L; Trial Management Group. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. Lancet. 2006;368:2053-60. [PMID: 17161727]
7. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al; Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784-92. [PMID: 16251534]
8. Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 2014;348:g366. [PMID: 24519768] doi:10.1136/bmj.g366
9. Paci E, Broeders M, Hofvind S, Puliti D, Duffy SW; EUROSCREEN Working Group. European breast cancer service screening outcomes: a first balance sheet of the benefits and harms. Cancer Epidemiol Biomarkers Prev. 2014;23:1159-63. [PMID: 24991022] doi:10.1158/1055-9965.EPI-13-0320
10. Smith RA. The value of modern mammography screening in the control of breast cancer: understanding the underpinnings of the current debates. Cancer Epidemiol Biomarkers Prev. 2014;23:1139-46. [PMID: 24991021] doi:10.1158/1055-9965.EPI-13-0946
11. Lauby-Secretan B, Scoccianti C, Loomis D, Benbrahim-Tallaa L, Bouvard V, Bianchini F, et al; International Agency for Research on Cancer Handbook Working Group. Breast-cancer screening-viewpoint of the IARC Working Group. N Engl J Med. 2015;372:2353-8. [PMID: 26039523] doi:10.1056/NEJMsr1504363
12. U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151:716-26. [PMID: 19920272] doi:10.7326/0003-4819-151-10-200911170-00008
13. Broeders M, Moss S, Nyströ m L, Njor S, Jonsson H, Paap E, et al; EUROSCREEN Working Group. The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. J Med Screen. 2012;19 Suppl 1:14-25. [PMID: 22972807]
14. Moss SM, Wale C, Smith R, Evans A, Cuckle H, Duffy SW. Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial. Lancet Oncol. 2015;16:1123-32. [PMID: 26206144] doi: 10.1016/S1470-2045(15)00128-X
15. U.S. Food and Drug Administration. Mammography Quality Standards Act and Program. Silver Spring, MD: U.S. Department of Health and Human Services; 2013. Accessed at www.fda.gov/Radiation-EmittingProducts/MammographyQualityStandards ActandProgram/default.htm on 12 January 2015.
16. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology-breast cancer. 2014. Accessed at www.nccn.org/professionals/physician-gls/f-guidelines.asp on 12 January 2015.
17. van Ravesteyn NT, Miglioretti DL, Stout NK, Lee SJ, Schechter CB, Buist DS, et al. Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk. Ann Intern Med. 2012;156:609-17. [PMID: 22547470] doi:10.7326/0003-4819-156-9-201205010-00002
18. Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O'Meara ES, et al. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med. 2012;156:635-48. [PMID: 22547473] doi:10.7326/0003-4819-156-9-201205010-00006
19. Schousboe JT, Kerlikowske K, Loh A, Cummings SR. Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Ann Intern Med. 2011;155:10-20. [PMID: 21727289] doi:10.7326/0003-4819-155-1-201107050-00003
20. Lansdorp-Vogelaar I, Gulati R, Mariotto AB, Schechter CB, de Carvalho TM, Knudsen AB, et al. Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. Ann Intern Med. 2014;161:104-12. [PMID: 25023249] doi:10.7326/M13-2867
21. de Gelder R, Heijnsdijk EA, Fracheboud J, Draisma G, de Koning HJ. The effects of population-based mammography screening starting between age 40 and 50 in the presence of adjuvant systemic therapy. Int J Cancer. 2015;137:165-72. [PMID: 25430053] doi:10.1002/ijc.29364
22. Mandelblatt JS, Fryback DG, Weinstein MC, Russell LB, Gold MR. Assessing the effectiveness of health interventions for cost-effectiveness analysis. Panel on Cost-Effectiveness in Health and Medicine. J Gen Intern Med. 1997;12:551-8. [PMID: 9294789]
23. Munoz D, Near AM, van Ravesteyn NT, Lee SJ, Schechter CB, Alagoz O, et al. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. J Natl Cancer Inst. 2014; 106. [PMID: 25255803] doi:10.1093/jnci/dju289
24. Fryback DG, Stout NK, Rosenberg MA, Trentham-Dietz A, Ku-ruchittham V, Remington PL. The Wisconsin Breast Cancer Epidemiology Simulation Model. J Natl Cancer Inst Monogr. 2006:37-47. [PMID: 17032893]
25. Mandelblatt J, Schechter CB, Lawrence W, Yi B, Cullen J. The SPECTRUM population model of the impact of screening and treatment on U.S. breast cancer trends from 1975 to 2000: principles and practice of the model methods. J Natl Cancer Inst Monogr. 2006:47-55. [PMID: 17032894]
26. Berry DA, Inoue L, Shen Y, Venier J, Cohen D, Bondy M, et al. Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. J Natl Cancer Inst Monogr. 2006: 30-6. [PMID: 17032892]
27. Plevritis SK, Sigal BM, Salzman P, Rosenberg J, Glynn P. A stochastic simulation model of U.S. breast cancer mortality trends from 1975 to 2000. J Natl Cancer Inst Monogr. 2006:86-95. [PMID: 17032898]
28. Lee S, Zelen M. A stochastic model for predicting the mortality of breast cancer. J Natl Cancer Inst Monogr. 2006:79-86. [PMID: 17032897]
29. Tan SY, van Oortmarssen GJ, de Koning HJ, Boer R, Habbema JD. The MISCAN-Fadia continuous tumor growth model for breast cancer. J Natl Cancer Inst Monogr. 2006:56-65. [PMID: 17032895]
30. Clarke LD, Plevritis SK, Boer R, Cronin KA, Feuer EJ. A comparative review of CISNET breast models used to analyze U.S. breast cancer incidence and mortality trends. J Natl Cancer Inst Monogr. 2006:96-105. [PMID: 17032899]
31. Gangnon RE, Sprague BL, Stout NK, Alagoz O, Weedon-Fekjær H, Holford TR, et al. The contribution of mammography screening to breast cancer incidence trends in the United States: an updated age-period-cohort model. Cancer Epidemiol Biomarkers Prev. 2015;24: 905-12. [PMID: 25787716] doi:10.1158/1055-9965.EPI-14-1286
32. Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, et al; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100, 000 women in 123 randomised trials. Lancet. 2012;379:432-44. [PMID: 22152853] doi:10.1016/S0140-6736(11)61625-5
33. Mandelblatt JS, Cronin K, de Koning H, Miglioretti DL, Schechter CS, Stout N. Modeling Report: Collaborative Modeling of U.S. Breast Cancer Screening Strategies. AHRQ Publication No. 14-05201-EF-4. Rockville, MD: U.S. Preventive Services Task Force; 2015. Accessed at www.uspreventiveservicestaskforce.org/Page/Document/modeling-report-collaborative-modeling-of-us-breast-cancer-1/breast-cancer-screening1 on 4 May 2015.
34. Chang Y, Schechter CB, van Ravesteyn NT, Near AM, Heijnsdijk EA, Adams-Campbell L, et al. Collaborative modeling of the impact of obesity on race-specific breast cancer incidence and mortality. Breast Cancer Res Treat. 2012;136:823-35. [PMID: 23104221] doi:10.1007/s10549-012-2274-3
35. Cho H, Klabunde CN, Yabroff KR, Wang Z, Meekins A, Lansdorp-Vogelaar I, et al. Comorbidity-adjusted life expectancy: a new tool to inform recommendations for optimal screening strategies. Ann Intern Med. 2013;159:667-76. [PMID: 24247672] doi:10.7326/0003-4819-159-10-201311190-00005
36. Holford TR, Cronin KA, Mariotto AB, Feuer EJ. Changing patterns in breast cancer incidence trends. J Natl Cancer Inst Monogr. 2006:19-25. [PMID: 17032890]
37. Kerlikowske K, Zhu W, Hubbard RA, Geller B, Dittus K, Braith-waite D, et al; Breast Cancer Surveillance Consortium. Outcomes of screening mammography by frequency, breast density, and post-menopausal hormone therapy. JAMA Intern Med. 2013;173:807-16. [PMID: 23552817] doi:10.1001/jamainternmed.2013.307
38. Dittus K, Geller B, Weaver DL, Kerlikowske K, Zhu W, Hubbard R, et al; Breast Cancer Surveillance Consortium. Impact of mammogra-phy screening interval on breast cancer diagnosis by menopausal status and BMI. J Gen Intern Med. 2013;28:1454-62. [PMID: 23760741] doi:10.1007/s11606-013-2507-0
39. Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making. 2006;26:391-400. [PMID: 16855127]
40. Stout NK, Rosenberg MA, Trentham-Dietz A, Smith MA, Robinson SM, Fryback DG. Retrospective cost-effectiveness analysis of screening mammography. J Natl Cancer Inst. 2006;98:774-82. [PMID: 16757702]
41. de Haes JC, de Koning HJ, van Oortmarssen GJ, van Agt HM, de Bruyn AE, van Der Maas PJ. The impact of a breast cancer screening programme on quality-adjusted life-years. Int J Cancer. 1991;49: 538-44. [PMID: 1917155]
42. Rosenberg RD, Yankaskas BC, Abraham LA, Sickles EA, Lehman CD, Geller BM, et al. Performance benchmarks for screening mam-mography. Radiology. 2006;241:55-66. [PMID: 16990671]
43. Kerlikowske K, Walker R, Miglioretti DL, Desai A, Ballard-Barbash R, Buist DS. Obesity, mammography use and accuracy, and advanced breast cancer risk. J Natl Cancer Inst. 2008;100:1724-33. [PMID: 19033562] doi:10.1093/jnci/djn388
44. Barlow WE, White E, Ballard-Barbash R, Vacek PM, Titus-Ernstoff L, Carney PA, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst. 2006;98:1204-14. [PMID: 16954473]
45. Sprague BL, Gangnon RE, Burt V, Trentham-Dietz A, Hampton JM, Wellman RD, et al. Prevalence of mammographically dense breasts in the United States. J Natl Cancer Inst. 2014;106. [PMID: 25217577] doi:10.1093/jnci/dju255
46. Tice JA, O'Meara ES, Weaver DL, Vachon C, Ballard-Barbash R, Kerlikowske K. Benign breast disease, mammographic breast density, and the risk of breast cancer. J Natl Cancer Inst. 2013;105: 1043-9. [PMID: 23744877] doi:10.1093/jnci/djt124
47. Mariotto AB, Wang Z, Klabunde CN, Cho H, Das B, Feuer EJ. Life tables adjusted for comorbidity more accurately estimate noncancer survival for recently diagnosed cancer patients. J Clin Epidemiol. 2013;66:1376-85. [PMID: 24035494] doi:10.1016/j.jclinepi.2013.07.002
48. Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA. 2001;285: 2750-6. [PMID: 11386931]
49. Schonberg MA, Davis RB, McCarthy EP, Marcantonio ER. External validation of an index to predict up to 9-year mortality of community-dwelling adults aged 65 and older. J Am Geriatr Soc. 2011;59:1444-51. [PMID: 21797837] doi:10.1111/j.1532-5415.2011.03523.x
50. van Ravesteyn NT, Stout NK, Schechter CB, Heijnsdijk EA, Alagoz O, Trentham-Dietz A, et al. Benefits and harms of mammog-raphy screening after age 74 years: model estimates of overdiagno-sis. J Natl Cancer Inst. 2015;107. [PMID: 25948872] doi:10.1093/jnci/djv103
51. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2012: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2012;62:129-42. [PMID: 22261986] doi:10.3322/caac.20143
52. Vilaprinyo E, Forné C, Carles M, Sala M, Pla R, Castells X, et al; Interval Cancer (INCA) Study Group. Cost-effectiveness and harm-benefit analyses of risk-based screening strategies for breast cancer. PLoS One. 2014;9:e86858. [PMID: 24498285] doi:10.1371/journal.pone.0086858
53. Pisano ED, Gatsonis C, Hendrick E, Yaffe M, Baum JK, Acharyya S, et al; Digital Mammographic Imaging Screening Trial (DMIST) Investigators Group. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med. 2005; 353:1773-83. [PMID: 16169887]
54. Kerlikowske K, Hubbard RA, Miglioretti DL, Geller BM, Yankas-kas BC, Lehman CD, et al; Breast Cancer Surveillance Consortium. Comparative effectiveness of digital versus film-screen mammogra-phy in community practice in the United States: a cohort study. Ann Intern Med. 2011;155:493-502. [PMID: 22007043] doi:10.7326/0003-4819-155-8-201110180-00005
55. Kerlikowske K, Zhu W, Tosteson AN, Sprague BL, Tice JA, Lehman CD, et al; Breast Cancer Surveillance Consortium. Identifying women with dense breasts at high risk for interval cancer: a cohort study. Ann Intern Med. 2015;162:673-81. [PMID: 25984843] doi:10.7326/M14-1465
56. Braithwaite D, Zhu W, Hubbard RA, O'Meara ES, Miglioretti DL, Geller B, et al; Breast Cancer Surveillance Consortium. Screening outcomes in older US women undergoing multiple mammograms in community practice: does interval, age, or comorbidity score affect tumor characteristics or false positive rates? J Natl Cancer Inst. 2013; 105:334-41. [PMID: 23385442] doi:10.1093/jnci/djs645
57. Lee CI, Lehman CD. Digital breast tomosynthesis and the challenges of implementing an emerging breast cancer screening technology into clinical practice. J Am Coll Radiol. 2013;10:913-7. [PMID: 24295940] doi:10.1016/j.jacr.2013.09.010
58. Friedewald SM, Rafferty EA, Rose SL, Durand MA, Plecha DM, Greenberg JS, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA. 2014;311:2499-507. [PMID: 25058084] doi:10.1001/jama.2014.6095
59. Park JY, Yi SY, Park HJ, Kim MS, Kwon HJ, Park NH, et al. Breast-specific gamma imaging: correlations with mammographic and clin-icopathologic characteristics of breast cancer. AJR Am J Roentgenol. 2014;203:223-8. [PMID: 24951219] doi:10.2214/AJR.13.11566
60. Rechtman LR, Lenihan MJ, Lieberman JH, Teal CB, Torrente J, Rapelyea JA, et al. Breast-specific gamma imaging for the detection of breast cancer in dense versus nondense breasts. AJR Am J Roent-genol. 2014;202:293-8. [PMID: 24450668] doi:10.2214/AJR.13.11585
61. Matamala N, Vargas MT, Gonzá lez-Cá mpora R, Miñ ambres R, Arias JI, Mené ndez P, et al. Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection. Clin Chem. 2015;61:1098-106. [PMID: 26056355] doi:10.1373/clinchem.2015.238691
62. Mavaddat N, Pharoah PD, Michailidou K, Tyrer J, Brook MN, Bolla MK, et al. Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst. 2015;107. [PMID: 25855707] doi:10.1093/jnci/djv036
63. Welch HG, Passow HJ. Quantifying the benefits and harms of screening mammography. JAMA Intern Med. 2014;174:448-54. [PMID: 24380095] doi:10.1001/jamainternmed.2013.13635
64. Etzioni R, Gulati R, Mallinger L, Mandelblatt J. Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening. Ann Intern Med. 2013;158:831-8. [PMID: 23732716] doi:10.7326/0003-4819-158-11-201306040-00008
65. Carter JL, Coletti RJ, Harris RP. Quantifying and monitoring over-diagnosis in cancer screening: a systematic review of methods. BMJ. 2015;350:g7773. [PMID: 25569206] doi:10.1136/bmj.g7773
66. Etzioni R, Xia J, Hubbard R, Weiss NS, Gulati R. A reality check for overdiagnosis estimates associated with breast cancer screening. J Natl Cancer Inst. 2014;106. [PMID: 25362701] doi:10.1093/jnci/dju315
67. Moynihan R, Nickel B, Hersch J, Beller E, Doust J, Compton S, et al. Public Opinions about Overdiagnosis: A National Community Survey. PLoS One. 2015;10:e0125165. [PMID: 25992887] doi:10.1371/journal.pone.0125165
68. Elmore JG, Harris RP. The harms and benefits of modern screening mammography [Editorial]. BMJ. 2014;348:g3824. [PMID: 24938686] doi:10.1136/bmj.g3824
69. Sprague BL, Stout NK, Schechter C, van Ravesteyn NT, Cevik M, Alagoz O, et al. Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts. Ann Intern Med. 2015;162:157-66. [PMID: 25486550] doi:10.7326/M14-0692
70. Fenton JJ, Xing G, Elmore JG, Bang H, Chen SL, Lindfors KK, et al. Short-term outcomes of screening mammography using computer-aided detection: a population-based study of medicare enrollees. Ann Intern Med. 2013;158:580-7. [PMID: 23588746] doi: 10.7326/0003-4819-158-8-201304160-00002
71. Miglioretti DL, Lange J, van Ravesteyn N, van den Broek JJ, Lee CI, Melnikow J, et al. Radiation-Induced Breast Cancer and Breast Cancer Death from Mammography Screening [Abstract]. Rockville, MD: Agency for Healthcare Research and Quality; 2015.
72. Trentham-Dietz A, Sprague BL, Hampton JM, Miglioretti DL, Nelson HD, Titus LJ, et al. Modification of breast cancer risk according to age and menopausal status: a combined analysis of five population-based case-control studies. Breast Cancer Res Treat. 2014;145:165-75. [PMID: 24647890] doi:10.1007/s10549-014-2905-y
73. Garcia-Closas M, Couch FJ, Lindstrom S, Michailidou K, Schmidt MK, Brook MN, et al; Gene ENvironmental Interaction and breast CAncer (GENICA) Network. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet. 2013; 45:392-8, 398e1-2. [PMID: 23535733] doi:10.1038/ng.2561
74. Stevens KN, Vachon CM, Couch FJ. Genetic susceptibility to triple-negative breast cancer. Cancer Res. 2013;73:2025-30. [PMID: 23536562] doi:10.1158/0008-5472.CAN-12-1699
75. Hoffmann TC, Del Mar C. Patients' expectations of the benefits and harms of treatments, screening, and tests: a systematic review. JAMA Intern Med. 2015;175:274-86. [PMID: 25531451] doi:10.1001/jamainternmed.2014.6016